High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment

Journal of Virology

Volumn 83, Issue 21, 2009, Pages 11407-11411

  Gonzalez, Veronica D ^a   Falconer, Karolin ^a   Blom, Kim G ^a   Reichard, Olle ^a   Mørn, Birgitte ^b   Laursen, Alex Lund ^c   Weis, Nina ^d,e   Alaeus, Annette ^a   Sandberg, Johan K ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d HVIDOVRE HOSPITAL   (Denmark)

^e Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CONTROLLED STUDY; FEMALE; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ANTIGENS, CD38; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; DISEASE PROGRESSION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-ALPHA; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; RIBAVIRIN; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; VIRAL LOAD; YOUNG ADULT;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 70350317461     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01211-09     Document Type: Article

References (30)

1. Balagopal, A., F. H. Philp, J. Astemborski, T. M. Block, A. Mehta, R. Long, G. D. Kirk, S. H. Mehta, A. L. Cox, D. L. Thomas, and S. C. Ray. 2008. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 135:226-233. (Pubitemid 351899010)
2. Bica, I., B. McGovern, R. Dhar, D. Stone, K. McGowan, R. Scheib, and D. R. Snydman. 2001. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin. Infect. Dis. 32:492-497.
3. Bjorkstrom, N. K., V. D. Gonzalez, K. J. Malmberg, K. Falconer, A. Alaeus, G. Nowak, C. Jorns, B. G. Ericzon, O. Weiland, J. K. Sandberg, and H. G. Ljunggren. 2008. Elevated numbers of Fc gamma RIIIA+ (CD16+) effector CD8 T cells with NK cell-like function in chronic hepatitis C virus infection. J. Immunol. 181:4219-4228.
4. Brenchley, J. M., D. A. Price, T. W. Schacker, T. E. Asher, G. Silvestri, S. Rao, Z. Kazzaz, E. Bornstein, O. Lambotte, D. Altmann, B. R. Blazar, B. Rodriguez, L. Teixeira-Johnson, A. Landay, J. N. Martin, F. M. Hecht, L. J. Picker, M. M. Lederman, S. G. Deeks, and D. C. Douek. 2006. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12:1365-1371.
5. Daar, E. S., H. Lynn, S. Donfield, E. Gomperts, M. W. Hilgartner, W. K. Hoots, D. Chernoff, S. Arkin, W. Y. Wong, C. A. Winkler, and Hemophilia Growth and Development Study. 2001. Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. J. Acquir. Immune Defic. Syndr. 26:466-472.
6. Daar, E. S., H. Lynn, S. Donfield, E. Gomperts, S. J. O'Brien, M. W. Hilgartner, W. K. Hoots, D. Chernoff, S. Arkin, W. Y. Wong, C. A. Winkler, and Hemophilia Growth and Development Study. 2001. Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs. J. Infect. Dis. 183:589-595.
7. Deeks, S. G., C. M. Kitchen, L. Liu, H. Guo, R. Gascon, A. B. Narvaez, P. Hunt, J. N. Martin, J. O. Kahn, J. Levy, M. S. McGrath, and F. M. Hecht. 2004. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 104:942-947.
8. De Rosa, F. G., S. Audagnotto, O. Bargiacchi, S. Garazzino, D. Aguilar Marucco, L. Veronese, F. Canta, S. Bonora, A. Sinicco, and G. Di Perri. 2006. Resolution of HCV infection after highly active antiretroviral therapy in a HIV-HCV coinfected patient. J. Infect. 53:e215-e218.
9. Douek, D. C., M. Roederer, and R. A. Koup. 2009. Emerging concepts in the immunopathogenesis of AIDS. Annu. Rev. Med. 60:471-484.
10. Falconer, K., V. D. Gonzalez, O. Reichard, J. K. Sandberg, and A. Alaeus. 2008. Spontaneous HCV clearance in HCV/HIV-1 coinfection associated with normalized CD4 counts, low level of chronic immune activation and high level of T cell function. J. Clin. Virol. 41:160-163.
11. Giorgi, J. V., L. E. Hultin, J. A. McKeating, T. D. Johnson, B. Owens, L. P. Jacobson, R. Shih, J. Lewis, D. J. Wiley, J. P. Phair, S. M. Wolinsky, and R. Detels. 1999. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J. Infect. Dis. 179:859-870.
12. Gonzalez, V. D., N. K. Bjorkstrom, K. J. Malmberg, M. Moll, C. Kuylenstierna, J. Michaelsson, H. G. Ljunggren, and J. K. Sandberg. 2008. Application of nine-color flow cytometry for detailed studies of the phenotypic complexity and functional heterogeneity of human lymphocyte subsets. J. Immunol. Methods 330:64-74.
13. Gonzalez, V. D., K. Falconer, J. Michaelsson, M. Moll, O. Reichard, A. Alaeus, and J. K. Sandberg. 2008. Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirin. Clin. Immunol. 128:46-56.
14. Greub, G., B. Ledergerber, M. Battegay, P. Grob, L. Perrin, H. Furrer, P. Burgisser, P. Erb, K. Boggian, J. C. Piffaretti, B. Hirschel, P. Janin, P. Francioli, M. Flepp, and A. Telenti. 2000. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 356:1800-1805. (Pubitemid 30954033)
15. Harcourt, G., E. Gomperts, S. Donfield, and P. Klenerman. 2006. Diminished frequency of hepatitis C virus specific interferon gamma secreting CD4+ T cells in human immunodeficiency virus/hepatitis C virus coinfected patients. Gut 55:1484-1487. (Pubitemid 44476795)
16. Hazenberg, M. D., S. A. Otto, B. H. van Benthem, M. T. Roos, R. A. Coutinho, J. M. Lange, D. Hamann, M. Prins, and F. Miedema. 2003. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 17:1881-1888.
17. Kim, A. Y., G. M. Lauer, K. Ouchi, M. M. Addo, M. Lucas, J. Schulze zur Wiesch, J. Timm, M. Boczanowski, J. E. Duncan, A. G. Wurcel, D. Casson, R. T. Chung, R. Draenert, P. Klenerman, and B. D. Walker. 2005. The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T-cell count in individuals coinfected with HIV-1. Blood 105:1170-1178.
18. Kovacs, A., L. Al-Harthi, S. Christensen, W. Mack, M. Cohen, and A. Landay. 2008. CD8(+) T cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus. J. Infect. Dis. 197:1402-1407.
19. Koziel, M. J., and M. G. Peters. 2007. Viral hepatitis in HIV infection. N. Engl. J. Med. 356:1445-1454.
20. Lempicki, R. A., M. A. Polis, J. Yang, M. McLaughlin, C. Koratich, D. W. Huang, B. Fullmer, L. Wu, C. A. Rehm, H. Masur, H. C. Lane, K. E. Sherman, A. S. Fauci, and S. Kottilil. 2006. Gene expression profiles in hepatitis C virus (HCV) and HIV coinfection: class prediction analyses before treatment predict the outcome of anti-HCV therapy among HIV-coinfected persons. J. Infect. Dis. 193:1172-1177.
21. Mandl, J. N., A. P. Barry, T. H. Vanderford, N. Kozyr, R. Chavan, S. Klucking, F. J. Barrat, R. L. Coffman, S. I. Staprans, and M. B. Feinberg. 2008. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat. Med. 14:1077-1087.
22. Merchante, N., J. A. Giron-Gonzalez, M. Gonzalez-Serrano, J. Torre-Cisneros, J. A. Garcia-Garcia, A. Arizcorreta, J. Ruiz-Morales, P. Cano-Lliteras, F. Lozano, C. Martinez-Sierra, J. Macias, and J. A. Pineda. 2006. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 20:49-57. (Pubitemid 41818114)
23. Monforte, A., D. Abrams, C. Pradier, R. Weber, P. Reiss, F. Bonnet, O. Kirk, M. Law, S. De Wit, N. Friis-Møller, A. N. Phillips, C. A. Sabin, J. D. Lundgren, and Data Collection on Adverse Events of Anti-HIV Drugs (D: A:D) Study Group. 2008. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 22:2143-2153.
24. Piroth, L., M. Grappin, L. Cuzin, Y. Mouton, O. Bouchard, F. Raffi, D. Rey, D. Peyramond, F. Gourdon, C. Drobacheff, M. L. Lombart, F. Lucht, J. M. Besnier, L. Bernard, P. Chavanet, and H. Portier. 2000. Hepatitis C virus co-infection is a negative prognostic factor for clinical evolution in human immunodeficiency virus-positive patients. J. Viral Hepat. 7:302-308.
25. Sarasin-Filipowicz, M., E. J. Oakeley, F. H. Duong, V. Christen, L. Terracciano, W. Filipowicz, and M. H. Heim. 2008. Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl. Acad. Sci. USA 105:7034-7039.
26. Sherman, K. E., S. D. Rouster, R. T. Chung, and N. Rajicic. 2002. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US Adult AIDS Clinical Trials Group. Clin. Infect. Dis. 34:831-837.
27. Shirakawa, H., A. Matsumoto, S. Joshita, M. Komatsu, N. Tanaka, T. Umemura, T. Ichijo, K. Yoshizawa, K. Kiyosawa, E. Tanaka, and Nagano Interferon Treatment Research Group. 2008. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 48:1753-1760.
28. Sulkowski, M. S., R. D. Moore, S. H. Mehta, R. E. Chaisson, and D. L. Thomas. 2002. Hepatitis C and progression of HIV disease. JAMA 288:199-206.
29. Thomas, D. L., J. Astemborski, D. Vlahov, S. A. Strathdee, S. C. Ray, K. E. Nelson, N. Galai, K. R. Nolt, O. Laeyendecker, and J. A. Todd. 2000. Determinants of the quantity of hepatitis C virus RNA. J. Infect. Dis. 181:844-851.
30. Zeitoun, J. D., V. Mallet, M. L. Chaix, J. P. Viard, S. Blanche, and S. Pol. 2007. Stable recovery from HCV in HIV-HCV co-infection under antiretroviral therapy. J. Clin. Virol. 40:71-73.